| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/27/2001 | CN1301155A Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same |
| 06/27/2001 | CN1301152A Transdermal therapeutic system containing pergolide |
| 06/27/2001 | CN1301131A Dipeptide apoptosis inhibitors and the use thereof |
| 06/27/2001 | CN1300614A Medicine for treating trigeminal neuralgia |
| 06/27/2001 | CN1300590A Use of coating as taste masking agent for oral preparation |
| 06/27/2001 | CN1067722C Adenoviral vectors |
| 06/27/2001 | CN1067685C Pyridazinoquinoline compounds |
| 06/27/2001 | CN1067684C Imidazo [1,5-1] quinolines for treatment of anxiety and sleep disorders |
| 06/27/2001 | CN1067683C Substituted morpholine derivatives and their use as therapeutic agents |
| 06/27/2001 | CN1067678C Alkyl heterocyclic compound and preparation method thereof, and medicinal composition containing that kind of compound |
| 06/27/2001 | CN1067567C Chinese traditional medicine for treating epilepsy |
| 06/26/2001 | US6251950 Administering to the patient an aliphatic-propargylamine or salt for the treatment of acute and chronic diseases in which cell death occurs by apoptosis or for the treatment of premature degeneration of cells in mammals |
| 06/26/2001 | US6251948 Trisubstituted guanidine useful for treating diseases of the nervous system in which the pathophysiology of the disease involves excessive excitation of nerve cells by agonists of glutamate/n-methyl-d-aspartate receptor |
| 06/26/2001 | US6251946 Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders |
| 06/26/2001 | US6251942 Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals |
| 06/26/2001 | US6251940 Administering to the mammal suffering from a diseases responsive to inhibit monocyte and/or macrophase and/or lymphocyte activation and of lymphocyte proliferation an amide derivative |
| 06/26/2001 | US6251935 Administration of a racemic alpha-lipoic acid, enantiomers and pharmaceutically acceptable salts, amides, esters or thioester, in reduced or oxidized form as antimigraine agent |
| 06/26/2001 | US6251929 Administering to a patient a hydantoin derivatives and salts as therapeutic and preventive agents for intractable vasculitis such as malignant rheumatoid arthritis(mra), periarteritis nodosa, wegener's granulomatosis etc. |
| 06/26/2001 | US6251928 Treatment of alzheimer's disease employing inhibitors of cathepsin D |
| 06/26/2001 | US6251925 An agonists for human beta-3 adrenoceptor |
| 06/26/2001 | US6251917 Benzamidoaldehydes and their use as cysteine protease inhibitors |
| 06/26/2001 | US6251916 For therapy of pain |
| 06/26/2001 | US6251914 Treating cytokine mediated diseases |
| 06/26/2001 | US6251909 Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 06/26/2001 | US6251908 Piperazine derivatives |
| 06/26/2001 | US6251907 1-(aryloxyalkyl)-4-(heteroaryl) piperazines and related compounds useful as antipsychotics and analgesics |
| 06/26/2001 | US6251904 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
| 06/26/2001 | US6251903 Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist |
| 06/26/2001 | US6251902 Dipeptide derivatives as growth hormone secretagogues |
| 06/26/2001 | US6251895 Stable crystalline dihydrate d olanzapine polymorph |
| 06/26/2001 | US6251894 1-(1,2-disubstituted piperidinyl)-4 (fused imidazole)-piperidine derivatives |
| 06/26/2001 | US6251893 Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| 06/26/2001 | US6251892 Neurotrophic low molecular weight small molecule n-oxides of heterocyclic esters, amides, thioesters and ketones; inhibitors of enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase or rotamase |
| 06/26/2001 | US6251865 Insulin-like growth factor agonist molecules |
| 06/26/2001 | US6251853 Pertussis toxin (ptx); beta-3 subunit of human g protein with not more than six wd repeat motifs; for the diagnosis of disorders, such as a disease associated with g protein dysregulation (i.e. hypertension) |
| 06/26/2001 | US6251669 Mammalian, non-tumor derived cells which divide, express neuron-specific markers, and give rise to progeny which differentiate into neuronal cells; for transplantation in treatment of alzheimer's/parkinson's diseases |
| 06/26/2001 | US6251617 Screening for modulators of glycine transport; incubate cells with modulator and measure amount of glycine transport activity |
| 06/26/2001 | US6251434 Preparations of non-steroidal analgesics |
| 06/26/2001 | US6251396 Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| 06/26/2001 | US6251391 Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons |
| 06/21/2001 | WO2001044514A2 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 06/21/2001 | WO2001044474A1 2871 receptor, a g-protein coupled receptor and methods of use thereof |
| 06/21/2001 | WO2001044473A2 Polypeptides and nucleic acids encoding same |
| 06/21/2001 | WO2001044472A1 Tnfr/opg-like molecules and uses thereof |
| 06/21/2001 | WO2001044448A2 Human oxidoreductase proteins |
| 06/21/2001 | WO2001044445A2 Human lyases and associated proteins |
| 06/21/2001 | WO2001044300A2 Brain specific binding members |
| 06/21/2001 | WO2001044268A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 06/21/2001 | WO2001044254A1 Cyclopenteneone derivatives |
| 06/21/2001 | WO2001044250A1 SUBSTITUTED 1,2,3-TRIAZOLO[1,5-a]QUINAZOLINES FOR ENHANCING COGNITION |
| 06/21/2001 | WO2001044249A1 Triazolo-pyrimidine derivatives as ligands for gaba receptors |
| 06/21/2001 | WO2001044248A1 Imidazopyrimidinyl and imidazopyridinyl derivatives |
| 06/21/2001 | WO2001044246A1 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 06/21/2001 | WO2001044245A1 Saccharin derivatives as orally active elastase inhibitors |
| 06/21/2001 | WO2001044244A1 Pyrazolo-pyridine derivatives as ligands for gaba receptors |
| 06/21/2001 | WO2001044243A2 Novel heteroaryl-diazabicycloalkanes |
| 06/21/2001 | WO2001044239A2 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 06/21/2001 | WO2001044229A1 Chemokine receptor binding heterocyclic compounds |
| 06/21/2001 | WO2001044227A1 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 06/21/2001 | WO2001044217A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 06/21/2001 | WO2001044213A1 New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 06/21/2001 | WO2001044211A1 Novel 3-oxo-2,1-benzisoxazol-1(3h)-carboxamides for treatment of cns diseases |
| 06/21/2001 | WO2001044207A2 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 06/21/2001 | WO2001044206A1 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 06/21/2001 | WO2001044205A2 Phenanthryl piperazinyl dicarboxylic acids as selective nmda receptor modulating agents |
| 06/21/2001 | WO2001044203A1 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses |
| 06/21/2001 | WO2001044200A2 Selective neurokinin antagonists |
| 06/21/2001 | WO2001044197A2 2-phenyl-quinoline derivatives and their use as contracting agent for smooth muscles |
| 06/21/2001 | WO2001044193A1 1,3,4-substituted piperidine analogs and uses thereof in treating addictions |
| 06/21/2001 | WO2001044170A1 Adamantane derivatives |
| 06/21/2001 | WO2001044164A1 Substituted norbornylamino derivatives, method for the production thereof, use thereof as a medicament or a diagnostic reagent and medicaments containing said compounds |
| 06/21/2001 | WO2001043775A2 Hydroxide-releasing agents as skin permeation enhancers |
| 06/21/2001 | WO2001043774A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 06/21/2001 | WO2001043773A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 06/21/2001 | WO2001043763A1 Betaglycan as an inhibin receptor and uses thereof |
| 06/21/2001 | WO2001043759A2 Use of 11cby popypeptides and polynuceotides |
| 06/21/2001 | WO2001043757A2 Composition comprising ingredients of panax ginseng and ginko biloba |
| 06/21/2001 | WO2001043753A2 Combination of ginseng and ginkgo to improve cognitive skills |
| 06/21/2001 | WO2001043745A1 The use of scopolamine salts |
| 06/21/2001 | WO2001043744A1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them |
| 06/21/2001 | WO2001043740A1 Antipsychotic heterocycle compounds |
| 06/21/2001 | WO2001043736A1 Drugs for relieving hemicrania |
| 06/21/2001 | WO2001043733A2 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation |
| 06/21/2001 | WO2001043728A1 Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy |
| 06/21/2001 | WO2001043726A1 System and method for extended delivery of a therapeutic agent with its receptor loading dose |
| 06/21/2001 | WO2001043697A2 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 06/21/2001 | WO2001043692A2 SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
| 06/21/2001 | WO2001043691A2 Fragments and antagonists of heat shock protein 60 |
| 06/21/2001 | WO2001043540A2 Methods for producing transgenic animals |
| 06/21/2001 | WO2001043525A2 Method for the preparation of citalopram |
| 06/21/2001 | WO2001016136A3 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 06/21/2001 | WO2001010411A3 Implantable active ingredient depot |
| 06/21/2001 | WO2000078972A8 Regulation with binding cassette transporter protein abc1 |
| 06/21/2001 | WO1998011243A9 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein |
| 06/21/2001 | US20010004643 Pharmaceutical composition with sotalol combination and their use in treatment of cardiac ailments |
| 06/21/2001 | US20010004639 Process for preparing arylacetylaminothiazoles |
| 06/21/2001 | DE19960917A1 Neue 3-Oxo-2,1-benzisoxazol-1(3H)-carboxamide zur Behandlung von ZNS-Erkrankungen New 3-oxo-2,1-benzisoxazol-1 (3H) -carboxamide for the treatment of CNS disorders |
| 06/21/2001 | DE19956486A1 Mehrschichtige Zubereitung zur gesteuerten, pulsartigen Abgabe von Wirkstoffen Multi-layer preparation for controlled, pulsatile delivery of active ingredients |
| 06/21/2001 | CA2401236A1 Method for the preparation of citalopram |
| 06/21/2001 | CA2395486A1 Saccharin derivatives as orally active elastase inhibitors |